



Journal Homepage: - www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/14629

DOI URL: <http://dx.doi.org/10.21474/IJAR01/14629>



RESEARCH ARTICLE

PRIMARY OVARIAN CARCINOID : A CASE REPORT AND REVIEW OF LITERATURE

Bahi S., Dorkami K., Asmouki H., Ait Benkaddour Y., Harou K., Aboufalah A. and Soummami A.

Department of Gynecology and Obstetric CHU Mohammed VI of Marrakesh, Morocco.

Manuscript Info

Manuscript History

Received: 28 February 2022

Final Accepted: 30 March 2022

Published: April 2022

Abstract

Carcinoid tumors are rare, slow-growing neoplasms that arise from the neuroendocrine cells. However, carcinoid tumors of the ovaries are uncommon, especially primary ovarian carcinoid tumors, which form approximately 0.3% of all carcinoid tumors. We present here a rare case of a 51-year-old patient who initially was presented for an ovarian teratoma and whose anatomico-pathological study showed that was a rare case of primary mixed insular and trabecular carcinoid tumor of the ovary. The complement of the therapeutic management in this case was done after a multidisciplinary consultation meeting.

Copy Right, IJAR, 2022,. All rights reserved.

Introduction:-

Carcinoid tumors are rare, slow-growing neoplasms that arise from the neuroendocrine cells [1]. The appendix is the most common site for carcinoid tumors, followed by the rectum, ileum, lungs, bronchi, and stomach [1]. However, carcinoid tumors of the ovaries are uncommon [2], especially primary ovarian carcinoid tumors [3], which form approximately 0.3% of all carcinoid tumors [2]. We present here a rare case of primary mixed insular and trabecular carcinoid tumor of the ovary.

Case Report:

51-year-old female patient with medical history of type 2 diabetes on oral anti-diabetic and hypertension under amlodipine, married, nulliparous, and menopause for 1 year, who presented initially with chronic pelvic pain evolving for 4 months, without any other associated signs, namely no diarrhea or vomiting.

The patient consulted a gynecologist in July 2020. The pelvic ultrasound showed limited right latero-uterine formation of 45 * 48 mm, with finely echogenic content, site of a macro calcification, of ovarian appearance. The patient was subsequently lost to sight, to consult again in December 2020 for the persistence of the same symptoms. A pelvic ultrasound was redone which showed a right latero-uterine mass with a fatty, tissue and calcium component in favor of a dermoid cyst of 55 * 47 mm. The result of the CA125 assay came back negative at 4.16 UI/mL. The patient therefore underwent surgery in December 2020 for a laparoscopic cystectomy. An oval cystic formation weighing 60g and measuring 6cm in large diameter. Its surface was regular smooth without exocystic vegetations was removed and sent to pathology which found the microscopic appearance of a malignant tumor proliferation on mature multi-tissue teratoma. An immunohistochemical study was done, and showed a mature teratoma associated with a carcinoid, based on the dosage of anti-Pan-cytokeratin antibodies, anti-chromogranin antibodies, anti-synaptophysin antibodies revealing a positivity of the tumor cells, but also anti-Ki67 antibodies whose labeling has been estimated at <1% of tumor cells.

Corresponding Author:- Bahi S.

Address:- Department of Gynecology and Obstetric CHU Mohammed VI of Marrakesh, Morocco.

The slides were read by two different pathologists, both finding the same results. A thoraco-abdomino-pelvic scan was done as part of the extension assessment, returned without anomalies.

The patient's case was then discussed in the multidisciplinary consultation meeting, and the decision was to do enlarged adenoid scolop hysterectomy, appendectomy and omentectomy.

The post op Pathology report didn't show any abnormalities.

The patient did not receive adjuvant chemotherapy with a good clinical course

Discussion:-

Primary ovarian carcinoid tumors are rare; and represent approximately 0.3% of all carcinoid tumors [4]. The age of presentation of ovarian carcinoid tumors has a large variation, ranging from 14 to 83 years with a peak in the perimenopausal or post-menopausal period [5,6]. In our case, the patient was 55 years old.

This is due to the fact that venous drainage from the ovary bypasses the liver and reaches directly into the systemic circulation. However, the other types of carcinoid tumor of the ovary are generally not associated with carcinoid syndrome [2, 6].

In our case, the patient did not have any signs and symptoms of carcinoid syndrome/carcinoid heart disease. Since diagnosis of carcinoid tumor was not suspected clinically, the patient was not investigated specifically for it.

The clinical symptoms of POC are usually not specific, abdominal pain, vaginal bleeding, and dysmenorrhea are occasionally reported. [7] Besides, rare symptoms like heart disease, diarrhea, constipation, hypoglycemia, and hirsutism have been reported in some cases. [8]

In our case, our patient presented none of the symptoms mentioned above apart from an isolated chronic pelvic pain.

Primary carcinoid tumor is histologically classified into insular, trabecular, mucinous and mixed types [5, 6]. The majority of the primary ovarian carcinoid occurs in association with solid teratoma or mucinous tumors or sertoli-leydig cell tumors; however, pure forms have also been documented [5, 6]. The pure forms are thought to develop either as one-sided development of a teratoma or from the enterochromaffin cells present in the ovary [6]. The most common histological type is insular, followed by trabecular and mucinous [6]. Grossly, pure primary carcinoid tumors are almost always unilateral [6, 9] with tan yellow and solid cut surface with few cystic areas and may vary in size from microscopic foci to almost 30 cm in the longest dimension.

In our case, it was a unilateral tumor, which was a yellowish solid on a cut section with few cystic areas.

Well-differentiated neuroendocrine tumors in the ovary are histologically similar to carcinoid/atypical carcinoid tumors in the other organs. However, in the ovaries, carcinoids and atypical carcinoids are often present as a part of the components of a teratoma or "specialized teratoma." In some cases, the neuroendocrine element may be the only tumor component in the ovary. Some studies show that approximately 14 % of ovarian carcinoid tumors were incidentally identified from pathological examination of excised ovaries for other reasons [3]. However, primary ovarian carcinoid tumors may be subdivided into four categories: insular, trabecular, mucinous, and strumal (trabecular carcinoid mixed with thyroid tissue) [5]

In the literature, the insular pattern is reported to be the most common subtype, and one-third of patients with insular carcinoid have presented with carcinoid syndrome before treatment [10]. It was suggested that the clinical symptoms of carcinoid were related to the size of the tumor [11]. The prognoses of insular, trabecular, and strumal carcinoid are favorable because these tumors in the ovary are rarely associated with metastasis [12], although adhesion to the omentum and to the intestine may occur when these tumors extend to the serosa.

However, there are some rare case reports that describe a metastatic carcinoid from ovarian primary tumor [14]. In other organs, atypical carcinoid is differentiated from carcinoid with a slightly increase in mitosis but a lack of significant nuclear pleomorphism and tumor necrosis.

IHC analysis,[14,15] such as Syn, CgA, CD56, PYY, and thyroglobulin, could also promote the diagnosis of POC, while in our case, the tumor tissues were positive for Syn, CgA, and anti Pan-cytokeratin. The specificity of CgA and 5-HIAA was 86% and 35%, respectively.[15] Besides, there was a study reporting that (there is a direct correlation between CgA and the disease severity) the sensitivity of CgA was associated with the disease severity.[16] Recently, Zhang et al[17] reported that there was a close correlation between Ki67 index and patient survival time, and a higher Ki67 index in metastatic carcinoid indicated a worse prognosis when compared with POC. In our case, the Ki67 index was positive and estimated <1%, and the metastatic assessment was negative.

The treatment strategy of POC should take into consideration histology type, patient age, and fertility needs.[18] For young females in early stage (stage I) who have pregnancy desires, fertility-sparing surgery should be preferred. For patients in late stage (stage II to IV), comprehensive staging and cytoreductive surgery is recommended. For patients with mucinous type of POC, omentectomy and para-aortic lymphadenectomy may be necessary. For insular and trabecular types, TAH+BSO should be selected. In addition, the recurrent and metastatic diseases are usually managed by a secondary surgical resection, chemotherapy, and molecular therapy. Chemotherapy could be used in the later stages OC.[17] our case study was classified as stage I, without chemotherapy conducted postoperatively. Satisfactory results were achieved in our patient during follow-up visit. Whether radiation therapy, hormonal therapy, and molecular therapy are useful or not has not been validated. Recently, some molecular medications were reported to help survival in gastrointestinal and pancreatic carcinoids, and is also proved to be useful in Ovarian carcinoid.[17,19]

Authors reported that the prognosis was good in insular, trabecular, and stromal carcinoids of POC when compared with mucinous or undifferentiated type.[11,20] In our case, our patient was insular type and exhibited good prognosis, up to now, she achieved satisfactory therapeutic effects without deterioration of general condition.

Conclusion:-

Primary ovarian carcinoid is a rare tumor of the ovaries [2] and is associated with good clinical outcome [6]. These tumors metastasize occasionally [5, 6] and should be treated as ovarian tumors of low malignant potential [5, 21].

The diagnosis of this tumor is important both therapeutically and prognostically a simple surgical excision is usually associated with a good prognosis in these patients [21] and it spares the patient from the morbidity and cost of pre and postoperative chemotherapy, which is usually the treatment protocol for most malignant ovarian tumors.

Bibliography:-

- Robertson RG, Geiger WJ, Davis NB (2006) Carcinoid tumors. *Am Fam Physician* 74:429–434
- Vergani D, Massironi L, Lombardi F, Fiorentini C (1998) Carcinoid heart disease from ovarian primary presenting with acute pericarditis and biventricular failure. *Heart* 80:623
- Kuscu E, Eroglu D, Ozdemir BH, Secme S, Haberal A (2003) Primary carcinoid tumor of the ovary: a case report. *Eur J Gynaecol Oncol* 24:574–576
- Vergani D, Massironi L, Lombardi F, Fiorentini C (1998) Carcinoid heart disease from ovarian primary presenting with acute pericarditis and biventricular failure. *Heart* 80:623
- Talerman A (1984) Carcinoid tumors of the ovary. *J Cancer Res Clin Oncol* 107:125–135
- Talerman A (2004) Germ cell tumors of the ovary In: Kurman RJ (ed) *Blaustein's pathology of the female genital tract*. 5th edn. Springer, New York
- Fiore MG, Rossi R, Covelli C, et al. Goblet-cell carcinoid of the ovary: a case report with ultrastructural analysis. *J Obstet Gynaecol* 2016;1–2.
- Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. *Gynecol Oncol* 2011;122:190–8.
- Robboy SJ, Scully RE, Norris HJ (1977) Prim noid of the ovary. *Obstet Gynecol* 49:202
- Robboy SJ, Norris HJ, Scully RE (1975) Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. *Cancer* 36(2):404–418
- Diaz-Montes TP, Rosenthal LE, Bristow RE, Grumbine FC (2006) Primary insular carcinoid of the ovary. *Gynecol Oncol* 101(1):175–178. doi:10.1016/j.ygyno.2005.10.015
- Davis KP, Hartmann LK, Keeney GL, Shapiro H (1996) Primary ovarian carcinoid tumors. *Gynecol Oncol* 61(2):259–265. doi:10.1006/gyno.1996.0136
- Vora M, Lacour RA, Black DR, et al. Neuroendocrine tumors in the ovary: histogenesis, pathologic differentiation, and clinical presentation. *Arch Gynecol Obstet* 2016;293:659–65.

14. Niu D, Li Z, Sun L, et al. Carcinoid arising from the teratomatous bronchial mucosa in a mature cystic teratoma of the ovary: a case report. *Int J GynecolPathol* 2018;37:123–7.
15. Seregni E, Ferrari L, Bajetta E, et al. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. *Ann Oncol* 2001;12(Suppl 2):S69–72.
16. Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. *GynecolOncol* 2011;122:190–8.
17. Zhang X, Jones A, Jenkins SM, et al. Ki67 proliferative index in carcinoid tumors involving ovary. *EndocrPathol* 2018;29:43–8.
18. Wright JD, Matsuo K, Huang Y, et al. Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. *ObstetGynecol* 2019;134:49–57.
19. Reed NS, Gomez-Garcia E, Gallardo-Rincon D, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary. *Int J Gynecol Cancer* 2014;24(9 Suppl 3):S35–41.
20. Sharma A, Bhardwaj M, Ahuja A. Rare case of primary trabecular carcinoid tumor of the ovary with unusual presentation. *Taiwan J ObstetGynecol* 2016;55:748–50.
21. Mungen E, Ertekin AA, Yergok YZ, Ergur AR, Baloglu H (1997) Primary mixed trabecular and insular carcinoid tumor of the ovary: a case report. *ActaObstetGynecolScand* 76:279–281.